CompletedPhase 3

Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock

France60 participantsStarted 2022-01-09

Plain-language summary

Because of dual oxygenation and oxygenator performance (PO2 postoxygenator up to 500 mmHg), hyperoxemia (PaO2 \> 150 mmHg) is frequent in veino-arterial ECMO, especially in the lower part of the body, which is mainly oxygenated by ECMO. By enhancing oxygen free radicals' production, hyperoxemia might favor gut, kidney and liver dysfunction. We hypothesize that targeting an extracorporeal normoxemia (i.e. PO2 postoxygenator between 100 and 150 mmHg) will decrease gut, kidney and liver dysfunctions, compared to a liberal extracorporeal oxygenation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient supported by veino-arterial ECMO for cardiogenic shock for less than 6 hours * Affiliation to social protection Exclusion Criteria: * Age \< 18 years old * Pregnancy * Opposition of the patient or his relatives * Cannulation during cardiopulmonary resuscitation * Cardiopulmonary resuscitation duration \> 10 minutes before ECMO implantation * Patient moribound on the day of randomization * Chronic hemodialysis * Chronic intestinal disease

What they're measuring

Enterocyte damage

Timeframe: At day 2

Trial details

NCT IDNCT04990349

SponsorCentre Hospitalier Universitaire de Besancon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-11-10

View on ClinicalTrials.gov More Cardiogenic Shock trials